The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
Official Title: A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients
Study ID: NCT00784888
Brief Summary: The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
Detailed Description: Group of patients using the same aromatase inhibitor
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Pfizer Investigational Site, Adana, , Turkey
Pfizer Investigational Site, Ankara, , Turkey
Pfizer Investigational Site, Ankara, , Turkey
Pfizer Investigational Site, Ankara, , Turkey
Pfizer Investigational Site, Bursa, , Turkey
Pfizer Investigational Site, Denizli, , Turkey
Pfizer Investigational Site, Edirne, , Turkey
Pfizer Investigational Site, Erzurum, , Turkey
Pfizer Investigational Site, Gaziantep, , Turkey
Pfizer Investigational Site, Istanbul, , Turkey
Pfizer Investigational Site, Istanbul, , Turkey
Pfizer Investigational Site, Izmir, , Turkey
Pfizer Investigational Site, Izmir, , Turkey
Pfizer Investigational Site, Kocaeli, , Turkey
Pfizer Investigational Site, Malatya, , Turkey
Pfizer Investigational Site, Trabzon, , Turkey
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR